Should I Buy MNDR? MNDR 2026 Analysis

Should You Buy Mobile-health Network Solutions (MNDR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.070

1 Day change

-7.76%

52 Week Range

40.000

Analysis Updated At

2026/01/26

Mobile-health Network Solutions (MNDR) is not a good buy for a beginner, long-term investor at this time. The stock has experienced a significant decline in price (-29.45% in the regular market and -19.63% pre-market), with no positive catalysts, no strong technical signals, and no recent news or financial data to support a recovery. Additionally, the lack of insider or hedge fund activity and weak future price trend probabilities make it unsuitable for long-term investment.

Technical Analysis

The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 45.546, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price direction. Key support lies at 0.98, with resistance at 1.355, but the stock is trading below the pivot level, which is bearish.

Options Data

Positive Catalysts

NULL identified. No news, insider activity, or hedge fund interest to act as positive drivers.

Neutral/Negative Catalysts

Significant price decline (-29.45% regular market, -19.63% pre-market). Weak future price trend probabilities (-5.63% in the next month). No recent news or financial data to support a recovery.

Financial Performance

No financial data available for analysis. Latest quarter data unavailable.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available. No Wall Street sentiment data provided.

Analyst Rating

Wall Street analysts forecast MNDR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNDR is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold